TrialJournal of diabetes investigation2018

Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.

Kazuyuki Tobe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.